A case report of nilotinib-induced irreversible interstitial lung disease

RATIONALE: Nilotinib is a second line tyrosine kinase inhibitor to treat patients with chronic myeloid leukemia after imatinib resistance or intolerance. Drug related pulmonary complication is known to be rare. We discuss a case of nilotinib-induced interstitial lung disease presenting with nonspeci...

Descripción completa

Detalles Bibliográficos
Autores principales: Cho, Jun Yeun, Lee, Ok-Jun, Kwon, Jihyun, Kim, Dohun, Shin, Yoon Mi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
6700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797569/
https://www.ncbi.nlm.nih.gov/pubmed/35089229
http://dx.doi.org/10.1097/MD.0000000000028701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8797569/
https://www.ncbi.nlm.nih.gov/pubmed/35089229
http://dx.doi.org/10.1097/MD.0000000000028701

Ejemplares similares